Angiotensin-converting enzyme inhibitor for post-transcatheter aortic valve implantation patients: study protocol for a multicenter randomized, open-label blinded endpoint control trial

Angiotensin-converting enzyme inhibitor for post-transcatheter aortic valve implantation patients: study protocol for a multicenter randomized, open-label blinded endpoint control trial

Abstract Background With the expanded utilization of transcatheter aortic valve implantation (TAVI) to younger and lower surgical risk patients with severe aortic stenosis (AS), optimal medical therapy after TAVI procedure has become the main concern. Renin-angiotensin system inhibitors (RASi) are w...

Full description

Bibliographic Details
Main Authors: Yan Biao Liao, Congying Xia, Yiheng Cheng, Qiao Li, Xin Wei, Yuanweixiang Ou, Fei Chen, Yijian Li, Qi Liu, Tianyuan Xiong, Zhengang Zhao, Yong Peng, Jiafu Wei, Yuan Feng, Mao Chen
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Trials
Subjects:
Aortic stenosis
Fosinopril
Left ventricle mass
Renin-angiotensin system inhibitor
Prognosis
Online Access:https://doi.org/10.1186/s13063-021-05411-5

Internet

https://doi.org/10.1186/s13063-021-05411-5

Similar Items